Eyeing first profits, Tillman Gerngross’s Avitide nabs one last VC round

John Carroll

When serial biotech entrepreneur and Dartmouth scientist Gerngross co-founded in early 2013, he had some specific ideas on how to quickly capitalize on a new-and-improved approach to purifying therapeutic proteins in a more efficient fashion that would make it easier for industry partners to manufacture a more potent drug. Today, the bioengineering professor and his team at nailed down the financing that they say will take the Lebanon, NH-based biotech to profitability in the next 12 to 24 months.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS